Crossmark

Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

Crossref DOI link: https://doi.org/10.1186/s40425-019-0551-y

Published Online: 2019-03-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Knudson, Karin M.

Hicks, Kristin C.

Alter, Sarah

Schlom, Jeffrey http://orcid.org/0000-0001-7932-4072
Gameiro, Sofia R.
Funding

Funding for this research was provided by:

Cooperative Research and Development Agreement (CRADA) between the NCI and NantBioScience. (N/A)

Intramural Research Program of the Center for Cancer Research, National Cancer Institute (N/A)
License Information

Text and Data Mining valid from 2019-03-21
More Information

Article History

Received: 16 October 2018

Accepted: 27 February 2019

First Online: 21 March 2019

Ethics approval and consent to participate

: All in vivo experiments were approved by the NCI/NIH Animal Care and Use Committee (ACUC).

: Not applicable.

: Authors from the National Cancer Institute do not have any competing interests to disclose. S.A. is an employee and shareholder of Altor Bioscience (a NantWorks company).

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.